Mark Delbello
Internal Medicine · Fort Wayne, INNPI 1548203300
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 430 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,949 and has fallen 99.8% since, to $3 in 2023. Among internal medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 430 payments — averaging $14.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$892
- Novo Nordisk$699
- AbbVie$516
- Merck$445
- Sanofi-aventis U.S. LLC$430
- plus $2K from 25 others
Across 13 payments — averaging $926.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$12K
What the payments were for
- Food & beverage$6,139100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $1,070 |
| Lilly USA, LLC | 64 | $892 |
| Novo Nordisk | 47 | $699 |
| AbbVie(2 entities) | 35 | $516 |
| Merck | 50 | $445 |
| Sanofi-aventis U.S. LLC | 24 | $430 |
| Boehringer Ingelheim | 25 | $390 |
| Johnson & Johnson | 40 | $282 |
| Pfizer | 17 | $256 |
| Amgen(2 entities) | 17 | $247 |
| Abbott | 10 | $165 |
| GSK | 8 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $104 |
| Xeris Pharmaceuticals, Inc. | 5 | $88 |
| Novartis | 4 | $58 |
| Amarin Pharma, Inc. | 3 | $45 |
| Amneal Pharmaceuticals LLC | 3 | $43 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Corcept Therapeutics | 2 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Astellas Pharma US Inc | 2 | $27 |
| Currax Pharmaceuticals LLC | 2 | $26 |
| Esperion Therapeutics, Inc. | 2 | $25 |
| Antares Pharma, Inc. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $19 |
| Insulet Corporation | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Travere Therapeutics, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,151 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 12 | $283 |
| Atorvastatin Calcium | 23 | $119 |
| Lisinopril | 11 | $82 |
| Amlodipine Besylate | 11 | $45 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Fort Wayne
- David IloFort Wayne$86K
- Anuradha KolliparaFort Wayne$30K
- Sumona KabirFort Wayne$28K
- Abhinav SinghGreenwood$733K
- Girish KunapareddyTerre Haute$329K
- Raj VuppalanchiIndianapolis$279K
- Joseph Arulandula Porte$251K
- Napoleon MamintaIndianapolis$116K
- Jennifer PaisleyLawrenceburg$112K
- Allon FriedmanIndianapolis$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.